Cannabis & Psychedelics Converging in USA Policy

For decades, cannabis and psychedelics occupied similar territory in American culture, one that is heavily stigmatized, federally restricted, and often discussed more through fear than science. Today, that landscape is changing fast. As cannabis continues moving deeper into the mainstream, psychedelics like psilocybin are beginning to follow a surprisingly familiar path.

Across the United States, lawmakers, researchers, and consumers are rethinking how altered states, plant-based compounds, and alternative therapies fit into public health and wellness. Cannabis dispensaries now exist in much of the country, ketamine clinics have expanded rapidly, and psychedelic-assisted therapy is gaining traction in scientific and political conversations alike.

A 2026 study¹ in AJPM Focus adds another layer to this evolving picture. Rather than testing psilocybin as a treatment, researchers examined who is actually using psilocybin in the United States today and how those patterns connect to broader substance use trends. The findings suggest that psychedelics are no longer a fringe phenomenon. Instead, they appear to be increasingly woven into the same cultural and policy shift that helped normalize cannabis.

Psilocybin Use Is Becoming More Visible

The study analyzed data from the 2024 National Survey on Drug Use and Health (NSDUH), which included more than 58,000 respondents across the United States. Researchers estimated that 2.78% of Americans reported using psilocybin within the past year.

That percentage may sound small at first glance, but nationally it represents millions of people. It also reflects growing public curiosity surrounding psychedelics as conversations around mental health, trauma, addiction, and alternative wellness continue expanding.

Researchers found psilocybin use was more common among:

• Young adults ages 18 to 25
• Males
• Non-Hispanic White individuals
• Higher-income households

The strongest associations, however, involved concurrent substance use. Individuals reporting cannabis use had dramatically higher odds of also reporting psilocybin use. Significant associations were also seen with alcohol, tobacco, LSD, ketamine, ecstasy, cocaine, and DMT-related substances. The findings reinforce a growing reality in substance research as many consumers are not viewing these compounds in isolation. Instead, cannabis, psychedelics, and other psychoactive substances are increasingly overlapping within broader wellness, recreational, and self-exploration cultures.

Cannabis and Psilocybin Use Overlap

One of the most striking findings from the study was the strong association between cannabis and psilocybin use. Past-year cannabis use carried one of the highest correlations with psilocybin consumption in the analysis. Though this overlap is not entirely surprising. Cannabis and psychedelics often share similar social environments, advocacy communities, and policy discussions. Many individuals interested in natural medicine, consciousness exploration, or alternative mental health treatments may already be familiar with cannabis before exploring psychedelics.

In recent years, online discussions around “plant medicine” have also blended the two categories together. Consumers frequently discuss cannabis alongside psilocybin microdosing, ketamine therapy, adaptogens, CBD, and holistic wellness approaches.

However, researchers emphasized that concurrent use raises important public health questions as well. Using multiple psychoactive substances together can complicate safety, increase unpredictability, and make harm reduction education more important. While some individuals intentionally combine cannabis with psychedelics to alter or intensify experiences, reactions can vary significantly depending on dosage, potency, mental state, and personal tolerance. For some, cannabis may deepen introspection during psychedelic experiences. For others, it can increase anxiety, confusion, or paranoia. As these substances become more culturally accepted, experts are increasingly emphasizing education over fear-based messaging.

Drug Policy Is Rapidly Shifting

The broader significance of the study extends beyond usage statistics. It reflects how quickly American drug policy conversations are evolving. Cannabis legalization helped reshape public attitudes toward once-taboo substances, and medical cannabis programs opened the door to broader discussions about therapeutic potential, criminal justice reform, patient autonomy, and harm reduction. Over time, many Americans began viewing cannabis less as a dangerous narcotic and more as a regulated wellness or medical product.

Psychedelics now appear to be entering a similar phase. Several cities and states have already moved to decriminalize or reduce penalties surrounding psilocybin possession. Oregon became the first state to legalize supervised psilocybin services, while Colorado later approved regulated psychedelic access programs as well. At the same time, federal agencies have shown increasing openness toward psychedelic research. Clinical trials involving psilocybin-assisted therapy for depression, PTSD, addiction, and end-of-life anxiety have expanded dramatically over the past decade.

Cannabis is also undergoing its own historic federal evolution as the U.S. government moves forward with reclassifying the plant from Schedule I to Schedule III. By formally recognizing its medical utility at the federal level, this shift fundamentally rewrites the framework for plant-based medicine. Although psilocybin remains strictly classified under Schedule I, researchers and policy advocates increasingly believe psychedelics will face a similar federal reassessment if clinical evidence continues to mount. In many ways, the normalization of cannabis has created the political and cultural blueprint for broader psychedelic reform.

Alternative Medicine Is Entering the Mainstream

The study’s findings also reflect changing consumer behavior around wellness and healthcare. Americans are increasingly exploring therapies outside traditional pharmaceutical models. CBD products, functional mushrooms, ketamine clinics, breathwork practices, meditation retreats, and psychedelic-assisted therapy are all gaining mainstream visibility. This does not necessarily mean conventional medicine is disappearing. Instead, many individuals appear to be combining traditional healthcare with alternative approaches in search of more personalized treatment options.

Mental health may be one of the biggest drivers behind this shift. Rising rates of anxiety, depression, burnout, trauma, and social isolation have fueled interest in therapies that address emotional well-being differently than standard medications alone.

Psilocybin research has generated significant attention because early clinical studies have shown potential benefits for treatment-resistant depression and other mental health conditions. Still, researchers caution that clinical environments differ substantially from recreational or unsupervised use. The new study did not examine therapeutic outcomes or whether participants used psilocybin medically, recreationally, spiritually, or experimentally. Instead, it simply captured prevalence patterns and associated behaviors. That distinction matters because public enthusiasm can sometimes outpace scientific understanding.

Why Surveillance and Education Matter

Researchers concluded that continued national surveillance will be essential as psychedelic attitudes and policies evolve. As cannabis legalization demonstrated, rapid cultural acceptance can create both opportunities and challenges. Greater access may reduce stigma and support medical research, but it also increases the need for accurate education around dosing, mental health risks, product quality, and safe consumption practices. The same will likely apply to psychedelics.

Psilocybin remains illegal federally, products remain largely unregulated outside limited state systems, and long-term population-level effects are still being studied. Researchers also noted that psilocybin use frequently overlaps with broader polysubstance use patterns, highlighting the importance of nuanced public health strategies rather than simplistic narratives.

One thing is clear, the conversation surrounding psychedelics is no longer confined to underground communities or academic conferences, but it is increasingly becoming part of mainstream American healthcare, wellness, and policy discussions, much like cannabis before it.

The Future of Cannabis and Psychedelic Reform

The convergence between cannabis and psychedelics may ultimately reshape how Americans think about medicine, mental health, and drug policy altogether. What once seemed politically impossible is now history unfolding in real time. Cannabis legalization expanded rapidly across the country within a single generation. Psychedelics may not follow the exact same timeline, but many signs suggest they are moving along a similar trajectory.

Studies like this one help reveal how public behavior is changing beneath the surface of policy debates. Millions of Americans are already experimenting with alternative substances, often alongside cannabis, as interest in nontraditional wellness continues to grow.

Whether lawmakers move quickly or cautiously, one thing is becoming increasingly clear: the boundaries between cannabis reform, psychedelic research, and alternative medicine are beginning to blur in ways that could redefine American drug policy for years to come.

^{1. R. Andrew Yockey, Amber Amis, Elise Devier, Aminul Apu, Rachel Hoopsick, Prevalence and Correlates of Past-Year Psilocybin Use in the U.S., 2024, USA, AJPM Focus, 2026, 100518, ISSN 2773-0654, https://doi.org/10.1016/j.focus.2026.100518}